Active substance
Vancomycin
- SFDA 24
- US FDA 71
- Health Canada 27
- US price lines 10
- NHS prices 2
- WHO EML 2
- Safety 7
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ALVANCO 1000MG POW. FOR INFUSION | 1000 mg | Powder for concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 30.60 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| ALVANCO 500MG POW. FOR INFUSION | 500 mg | Powder for concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 33.95 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| COLAT 500 mg powder for solution for infusion | 500 mg | Solution for infusion · Intravenous use | 1 Vial | SAR 37.70 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| TOSTAF 500 mg Vial | 500 mg | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 18.00 | Generic · Prescription | LES LABORATOIRES MEDIS | Valid |
| Taycan | 500 mg | Powder for concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 30.60 | Generic · Prescription | Advanced Pharmaceutical Industries | Valid |
| Taycan | 1000 mg | Powder for concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 36.05 | Generic · Prescription | Advanced Pharmaceutical Industries | Valid |
| Ultavan | 5 mg/ml | Intravenous infusion · Intravenous use | 12 Bag | SAR 775.15 | Generic · Prescription | Branch of jazeera pharmaceutical industries company | Valid |
| Ultavan | 5 mg/ml | Intravenous infusion · Intravenous use | 12 Bag | SAR 650.15 | Generic · Prescription | Branch of jazeera pharmaceutical industries company | Valid |
| VANCO 1000 mg powder for solution for injection or infusion | 1000 mg | Powder for solution for injection/infusion · Parenteral use | 1 Vial | SAR 57.90 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| VANCO 500 mg powder for solution for injection or infusion | 500 mg | Powder for solution for injection/infusion · Parenteral use | 1 Vial | SAR 41.90 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| VANCOLON 0.5 GM/Vial | 50 mg/ml | Powder for solution for injection/infusion · Intravenous use | 10 Vial | SAR 363.00 | Generic · Prescription | GULF PHARMACEUTICAL INDUSTIRES- JULPHAR | Valid |
| VANCOLON 0.5GM-VIAL I.V. | 50 mg/ml | Powder for solution for injection/infusion · Parenteral use | 1 Vial | SAR 46.55 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| VANCOLON 1GM POWDER FOR I.V. INFUSION | 1 g | Powder for solution for injection/infusion · Parenteral use | 1 Vial | SAR 58.60 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| Vanco | 500 mg | Powder for solution for injection/infusion · Parenteral use | 10 Vial | SAR 367.35 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Vanco | 1 g | powder for solution for injection\nfusion · Parenteral use | 10 Vial | SAR 504.40 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Vanin | 1000 mg | Injection · Intravenous use | 10 Vial | SAR 306.00 | Generic · Prescription | Saudi Amarox | Valid |
| Vanin | 500 mg | Injection · Intravenous use | 10 Vial | SAR 306.00 | Generic · Prescription | Saudi Amarox | Valid |
| Sterile VANCOMYCIN HCL, USP | 500 mg | Lyophilisate for solution for injection · Intravenous use | 10 Vial | SAR 180.25 | Generic · Prescription | HOSPIRA INC | Withdrawn by MAH · Not Marketed |
| Sterile VANCOMYCIN HCL, USP | 1 g | Lyophilisate for solution for injection · Intravenous use | 10 Vial | SAR 340.30 | Generic · Prescription | HOSPIRA INC | Withdrawn by MAH · Not Marketed |
| VANCOCIN-CP 500MG-10 ML. VIAL | 50 mg/ml | Powder for solution for injection/infusion · Parenteral use | 1 Vial | SAR 51.75 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| VANCOMYCIN ALPHARMA 1GM VIAL | 1 g | Lyophilisate for solution for injection · Parenteral use | 1 Vial | SAR 53.85 | Generic · Prescription | SUDAIR PHARMA COMPANY | Invalid · Not Marketed |
| VANCOMYCIN ALPHARMA 500MG VIAL | 500 mg | Lyophilisate for solution for injection · Parenteral use | 1 Vial | SAR 31.60 | Generic · Prescription | SUDAIR PHARMA COMPANY | Invalid · Not Marketed |
| VANCOMYCIN HCL 1 G VIAL FOR INFUSION | 1 g | Lyophilisate for solution for injection · Parenteral use | 1 Vial | SAR 87.00 | Generic · Prescription | HOSPIRA INC | Withdrawn by MAH · Not Marketed |
| VANCOMYCIN HCL 500MG VIAL FOR INFUSION | 500 mg | Lyophilisate for solution for injection · Parenteral use | 1 Vial | SAR 50.60 | Generic · Prescription | HOSPIRA INC | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE EXACERBATION OF BRONCHIECTASIS (NON-CYSTIC FIBROSIS); ANTIBIOTIC SURGICAL PROPHYLAXIS; BACTERIAL MENINGITIS; BACTERIAL SKIN INFECTIONS - ERYSIPELAS AND CELLULITIS; BACTERIAL SKIN INFECTIONS - GAS GANGRENE; BACTERIAL SKIN INFECTIONS - NECROTIZING FASCIITIS; BACTERIAL SKIN INFECTIONS - PURULENT SKIN AND SOFT TISSUE INFECTIONS (CUTANEOUS ABSCESSES, FURUNCLES, CARBUNCLES); BACTERIAL SKIN INFECTIONS - SURGICAL SITE INFECTIONS; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT - CLOSTRIDIUM DIFFICILE INFECTIONS; BARIATRIC SURGERY; COMMUNITY ACQUIRED PNEUMONEA; DENTAL ABSCESS; DIARRHEA; ENDOCARDITIS; HIP AND KNEE REPLACEMENT SURGERY; HOSPITAL AND VENTILATER ACQUIRED PNEUMONIA; INTRA-ABDOMINAL INFECTIONS; MATERNAL AND CHILD HEALTHCARE- GROUP B STREPTOCOCCUS; OSTEOMYELITIS; PERITONITIS; PREVENTION AND CHEMOPROPHYLAXIS OF BACTERIAL MENINGITIS- MENINGITIS, MENINGOCOCCAL INFECTIONS PREVENTION (CHEMOPROPHYLAXIS); Pyogenic Arthritis; RENAL TRANSPLANT; Septic Shock; SICKLE CELL DISEASE - ACS MANAGEMENT; TRAVEL RELATED INFECTIONS-TREATMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VANCOCIN HYDROCHLORIDE | EQ 250MG BASE/5ML | for solution · oral | ANI PHARMS | Prescription | 13 Jul 1983 |
| VANCOCIN HYDROCHLORIDE | EQ 125MG BASE; EQ 250MG BASE | capsule · oral | ANI PHARMS | Prescription | 15 Apr 1986 |
| VANCOMYCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 5GM BASE/VIAL; EQ 10GM BASE/VIAL; EQ 750MG BASE/VIAL | injectable · injection | FRESENIUS KABI USA | Prescription | 17 Mar 1987 |
| VANCOMYCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL | injectable · injection | HOSPIRA | Prescription | 4 Aug 1988 |
| VANCOMYCIN HYDROCHLORIDE | EQ 1GM BASE/VIAL; EQ 750MG BASE/VIAL; EQ 1.5GM BASE/VIAL | injectable · injection | HOSPIRA | Prescription | 4 Aug 1988 |
| VANCOMYCIN HYDROCHLORIDE | EQ 5GM BASE/VIAL; EQ 10GM BASE/VIAL | injectable · injection | HOSPIRA | Prescription | 21 Dec 1990 |
| VANCOMYCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL | injectable · injection | HOSPIRA | Prescription | 29 Oct 1992 |
| VANCOMYCIN HYDROCHLORIDE | EQ 1GM BASE/VIAL; EQ 750MG BASE/VIAL | injectable · injection | HOSPIRA | Prescription | 29 Oct 1992 |
| VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER | EQ 500MG BASE/100ML (EQ 5MG BASE/ML); EQ 750MG BASE/150ML (EQ 5MG BASE/ML); EQ 1GM BASE/200ML (EQ 5MG BASE/ML); EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML); EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML) | solution · intravenous | BAXTER HLTHCARE | Prescription | 29 Apr 1993 |
| VANCOMYCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | EUROFARMA | Prescription | 30 Jun 2008 |
| VANCOMYCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | MYLAN LABS LTD | Prescription | 30 Dec 2008 |
| VANCOMYCIN HYDROCHLORIDE | EQ 5GM BASE/VIAL | injectable · injection | MYLAN LABS LTD | Prescription | 30 Dec 2008 |
| VANCOMYCIN HYDROCHLORIDE | EQ 10GM BASE/VIAL | injectable · injection | MYLAN LABS LTD | Prescription | 19 Sep 2011 |
| VANCOMYCIN HYDROCHLORIDE | EQ 125MG BASE; EQ 250MG BASE | capsule · oral | PAI HOLDINGS | Prescription | 9 Apr 2012 |
| VANCOMYCIN HYDROCHLORIDE | EQ 125MG BASE; EQ 250MG BASE | capsule · oral | STRIDES PHARMA | Prescription | 9 Apr 2012 |
| VANCOMYCIN HYDROCHLORIDE | EQ 5GM BASE/VIAL; EQ 10GM BASE/VIAL | injectable · injection | SAGENT PHARMS | Prescription | 10 Aug 2012 |
| VANCOMYCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | HIKMA PHARMS | Prescription | 28 Dec 2015 |
| VANCOMYCIN HYDROCHLORIDE | EQ 5GM BASE/VIAL; EQ 10GM BASE/VIAL | injectable · injection | XELLIA PHARMS APS | Prescription | 28 Dec 2015 |
| VANCOMYCIN HYDROCHLORIDE | EQ 100GM BASE | powder · intravenous | SAMSON MEDCL | Prescription | 6 Jan 2016 |
| VANCOMYCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 5GM BASE/VIAL; EQ 10GM BASE/VIAL | injectable · injection | GLAND | Prescription | 21 Jan 2016 |
| VANCOMYCIN HYDROCHLORIDE | EQ 5GM BASE/VIAL; EQ 10GM BASE/VIAL | injectable · injection | EUGIA PHARMA | Prescription | 29 Mar 2016 |
| VANCOMYCIN HYDROCHLORIDE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | EUGIA PHARMA | Prescription | 31 Mar 2016 |
| FIRVANQ KIT | EQ 25MG BASE/ML; EQ 50MG BASE/ML | for solution · oral | AZURITY | Prescription | 26 Jan 2018 |
| VANCOMYCIN HYDROCHLORIDE | EQ 750MG BASE/VIAL; EQ 1.25GM BASE/VIAL; EQ 1.5GM BASE/VIAL; EQ 1.75GM BASE/VIAL; EQ 2GM BASE/VIAL | powder · intravenous | MYLAN LABS LTD | Prescription | 10 Jul 2018 |
| VANCOMYCIN HYDROCHLORIDE | EQ 750MG BASE/VIAL | injectable · injection | HIKMA PHARMS | Prescription | 3 Oct 2018 |
46 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| JAMP VANCOMYCIN | 02407744 | 125 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| JAMP VANCOMYCIN | 02407752 | 250 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| VANCOCIN | 00788716 | 250 MG | CAPSULE · ORAL | SEARCHLIGHT PHARMA INC |
| VANCOCIN | 00800430 | 125 MG | CAPSULE · ORAL | SEARCHLIGHT PHARMA INC |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP | 02342855 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP | 02342863 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP | 02405822 | 5 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP | 02405830 | 10 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP | 02435713 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | GENERIC MEDICAL PARTNERS INC |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP | 02435721 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | GENERIC MEDICAL PARTNERS INC |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02139243 | 5 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02139375 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02139383 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02241807 | 10 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02394626 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02394634 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02394642 | 5 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02406535 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | MARCAN PHARMACEUTICALS INC |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02406543 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | MARCAN PHARMACEUTICALS INC |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02406551 | 5 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | MARCAN PHARMACEUTICALS INC |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02502593 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | JAMP PHARMA CORPORATION |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02531127 | 5 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | HIKMA CANADA LIMITED |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02532999 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | EUGIA PHARMA INC. |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02533006 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | EUGIA PHARMA INC. |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 02543974 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | HIKMA CANADA LIMITED |
2 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | VANCOMYCIN 25 MG/ML ORAL SOLN | $0.67288 | per ML | 23 Sep 2026 |
| US NADAC | VANCOMYCIN 25 MG/ML ORAL SOLN | $0.39002 | per ML | 23 Sep 2026 |
| US NADAC | VANCOMYCIN 250 MG/5 ML ORAL SOL | $0.8007 | per ML | 17 Dec 2025 |
| US NADAC | VANCOMYCIN 250 MG/5 ML ORAL SOL | $0.70181 | per ML | 23 Sep 2026 |
| US NADAC | VANCOMYCIN 250 MG/5 ML ORAL SOL | $2.90936 | per ML | 17 Dec 2025 |
| US NADAC | VANCOMYCIN 50 MG/ML ORAL SOLN | $0.70181 | per ML | 23 Sep 2026 |
| US NADAC | VANCOMYCIN 50 MG/ML ORAL SOLN | $0.8007 | per ML | 17 Dec 2025 |
| US NADAC | VANCOMYCIN 500 MG VIAL | $2.3054 | per EA | 17 Dec 2025 |
| US NADAC | VANCOMYCIN HCL 125 MG CAPSULE | $1.32898 | per EA | 23 Sep 2026 |
| US NADAC | VANCOMYCIN HCL 250 MG CAPSULE | $2.59757 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Vancomycin 125mg capsules | £92.30 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Vancomycin 250mg capsules | £131.74 | 28 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.2. Watch group antibiotics · complementary
First choice: Necrotising fasciitis; Second choice: Neutropaenia (high-risk)
Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection - 6.2.2. Watch group antibiotics · core
First choice: Endophthalmitis (co-prescribed with ceftazidime); First choice: Endophthalmitis (co-prescribed with ceftriaxone); Second choice: Intestinal infections due to Clostridioides difficile
Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection | Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
Safety signals and safety-related labeling changes
- US FDA 18 Aug 2026 TYZAVAN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 Jun 2026 VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations - US FDA 27 Jun 2025 VANCOMYCIN HYDROCHLORIDE — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 4 Apr 2022 VANCOMYCIN HYDROCHLORIDE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Dec 2021 VANCOCIN HYDROCHLORIDE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 29 Jan 2021 FIRVANQ KIT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 29 Jan 2021 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.